Abbott Laboratories (ABT)

[DewDiligence]

ABT 3Q22 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency)   
 Medical devices*  35%        +6%     
 Diagnostics       35%        -1%     
 Nutrition         17%       -10%     
 Drugs†            13%       +12%

3Q22 COVID-diagnostics sales were $1.7B, 46% of 3Q22 diagnostics sales.

61% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.